Artivion Inc (AORT)vsEli Lilly and Company (LLY)
AORT
Artivion Inc
$19.40
-3.48%
HEALTHCARE · Cap: $998.73M
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 17843% more annual revenue ($86.46B vs $481.88M). LLY leads profitability with a 31.9% profit margin vs -3.6%. LLY appears more attractively valued with a PEG of 1.36. LLY earns a higher WallStSmart Score of 74/100 (B).
AORT
Hold35
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.3%
Fair Value
$31.25
Current Price
$19.40
$11.85 premium
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.9%
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
AORT profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.28 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 35/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?